Different doses or strenghts? [General Sta­tis­tics]

posted by kumarnaidu – Mumbai, India, 2013-11-21 15:00 (4602 d 04:28 ago) – Posting: # 11935
Views: 10,496

Hi all,
I got one protocol for review. In that they have given some different design which I want to share with you.
They are having two cohorts. In cohort 1 15 patients will receive T (5 subjects in each dose category) and 15 will receive R
T1, T2 and T3 are different doses. In Cohort 2 - Subject received T in cohort 1 will receive R and Subject received R will receive T (T1 or T2 or T3 based on some set criteria )

Cohort 1 (n = 15)
T1 (n1 = 5)
T2 (n2 = 5)
T3 (n3 = 5)
R (n = 15)

Cohort 2 (n = 15)
R(n = 15)


T1 or T2 or T3 (n = 15)

Bioequivalence will be evaluated in cohort 2. And cohort one will be used for dose identification. According to me we need to use parallel design here for analysis in cohort 2 but what about period and sequence effect.:confused:

Kumar Naidu

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
340 visitors (0 registered, 340 guests [including 14 identified bots]).
Forum time: 20:28 CEST (Europe/Vienna)

The real struggle is not between the right and the left
but between the party of the thoughtful
and the party of the jerks.    Jimmy Wales

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5